Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 3/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | CASP9 | P55211 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676633 | 0.72 | CYP1A2 (0.41) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL1738014 | 0.71 | AHR (0.45) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL158071 | 0.68 | PNMT (0.35) | MAOBHTR2C | |
| SCHEMBL2940889 | 0.64 | TRPA1 (0.44) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL2313287 | 0.64 | AHR (0.70) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL599812 | 0.63 | CYP1A2 (0.44) | AHRPDK2TDP2CASP3CASP7 | |
| SCHEMBL334119 | 0.63 | TRPA1 (0.42) | CYP1A2MAOANPC1SMN1; SMN2MAPT | |
| SCHEMBL16397452 | 0.63 | KDM4E (0.32) | CYP1A2NPC1MAPT | |
| SCHEMBL1750074 | 0.61 | MAOA (0.42) | CYP1A2MAOANPC1SMN1; SMN2CYP2A6 | |
| SCHEMBL1750072 | 0.61 | MAOA (0.42) | CYP1A2MAOANPC1SMN1; SMN2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | claimed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | claimed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | claimed |
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| EP-2776393-B1 | NAMPT INHIBITORS | ABBVIE INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9758511-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170253562-A1 | Nampt Inhibitors | ABBVIE INC (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170135994-A9 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170065575-A1 | NAMPT INHIBITORS | ABBVIE INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160193209-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160184281-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2013170118-A1 | THIAZOLECARBOXAMIDE DERIVATIVES FOR USE AS NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013170113-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| EP-2640698-A1 | NAMPT AND ROCK INHIBITORS | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2640704-A1 | NAMPT INHIBITORS | Abbvie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2013067710-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2012067963-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012067965-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122924-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122924-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | AHR 3942/4885PDK2 370/4885TDP2 2436/4885 |
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | AHR 3376/4885PDK2 400/4885TDP2 1393/4885 |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | AHR 4268/4885PDK2 700/4885TDP2 1805/4885 |
| US-20170253562-A1 | Nampt Inhibitors | NAMPT, NNMT, NAPRT | AHR 3942/4885PDK2 370/4885TDP2 2436/4885 |
| US-20170065575-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | AHR 3942/4885PDK2 370/4885TDP2 2436/4885 |
| US-20160184281-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | AHR 3942/4885PDK2 370/4885TDP2 2436/4885 |
| US-20170135994-A9 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | AHR 3942/4885PDK2 370/4885TDP2 2436/4885 |
| US-20160193209-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | AHR 3942/4885PDK2 370/4885TDP2 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.